Nao Kawaguchi

Nao Kawaguchi

Auto-generated profile, based on publicly available information

Nao Kawaguchi

Drug Development and Regulatory Science Division, Shionogi & Co., Ltd. , Osaka

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
NKNao Kawaguchi
Nao Kawaguchi
TKTakayuki Katsube
Takayuki Katsube
RERoger Echols
Roger Echols
TWToshihiro Wajima
Toshihiro Wajima
Cefiderocol is a novel siderophore cephalosporin with antibacterial activity against Gram-negative bacteria, including carbapenem-resistant strains. The standard dosing regimen of cefiderocol is 2 g administered every 8 hours over 3 hours infusion in patients with creatinine clearance (CrCL) of 60 to 119 ml/min, and it is adjusted for patients with <60 ml/min or ≥120 ml/min CrCL.

1 June 2020 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
KFKazuya Fukumura
Kazuya Fukumura
NKNao Kawaguchi
Nao Kawaguchi
TIToru Ishibashi
Toru Ishibashi
RKRyuji Kubota
Ryuji Kubota
YTYukio Tada
Yukio Tada
EOEriko Ogura
Eriko Ogura
Background Naldemedine is a peripherally acting μ-opioid receptor antagonist that is indicated to treat opioid-induced constipation. Objectives To assess the potential for drug-drug interactions between a single oral dose of naldemedine and the oral P-glycoprotein inhibitor cyclosporine, cytochrome P450 (CYP) 3A inhibitors itraconazole and fluconazole, and CYP3A inducer rifampin. Methods Three Phase 1, open-label studies were conducted in healthy subjects. In the P-glycoprotein inhibitor study, subjects received naldemedine 0.4 mg alone or coadministered with cyclosporine 600 mg. In the CYP3A inhibitors study, subjects in separate cohorts received naldemedine 0.2 mg alone or with itraconazole or fluconazole. In the CYP3A inducer study, subjects received naldemedine 0.2 mg alone or with rifampin 600 mg. Geometric mean ratios and 90 % confidence intervals were used to evaluate the effects of coadministered drugs on naldemedine maximum plasma concentration (Cmax) and the area under the concentration-time curve (AUC). Safety assessments included occurrence of adverse events (AEs), laboratory parameters, vital signs, and electrocardiography results. Results A total of 56 subjects were enrolled (n = 14 in each cohort). Cyclosporine increased naldemedine AUC0–inf 1.78-fold and Cmax 1.45-fold. Itraconazole and fluconazole increased naldemedine AUC0–inf 2.91-fold and 1.90-fold, and Cmax 1.12-fold and 1.38-fold, respectively. Rifampin decreased naldemedine AUC0–inf by 83% and Cmax by 38%. Across studies, AEs were generally mild. Laboratory, vital sign, or electrocardiogram assessments produced no clinically significant findings. Conclusions Coadministration of naldemedine with a P-glycoprotein inhibitor or a strong/moderate CYP3A inhibitor increases naldemedine exposure; coadministration with a strong CYP3A inducer decreases its exposure. Coadministration of naldemedine with cyclosporine, itraconazole, fluconazole, or rifampin was generally safe and well tolerated.

15 December 2023 in The Japanese Journal of SURGICAL METABOLISM and NUTRITION
Verified
Journal Article
Open access
PDF file
ATAtsushi Tomioka
Atsushi Tomioka
MAMitsuhiro Asakuma
Mitsuhiro Asakuma
NKNao Kawaguchi
Nao Kawaguchi
KKKoji Komeda
Koji Komeda
SLSang-Woong Lee
Sang-Woong Lee
膵癌は5年生存率が極めて低く, 最も予後不良な悪性腫瘍であるが,少しずつ成績は向上してきていると言える. 既に術前補助化学療法と術後補助化学療法は標準療法として実践されている. 切除可能膵癌に対してはこれらの治療を計画通り施行する事が生存率を高めるために重要になってくるが, 膵癌ではさまざまな理由から化学療法の忍容性が十分でない事が多い. 化学療法に対する忍容性を高めるために, さまざまな角度からのサポートが必要である. その中でも不可欠なのが栄養面でのサポートであり, それには一般的な栄養管理に加えて, 膵癌・膵疾患の特殊性を理解した栄養管理を理解して実践する事が重要である.

15 June 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
SBStuart Byrne
Stuart Byrne
TBTakamichi Baba
Takamichi Baba
NKNao Kawaguchi
Nao Kawaguchi
AYAtsuko Yamamoto
Atsuko Yamamoto
YNYoshiyuki Nakano
Yoshiyuki Nakano
TUTakeki Uehara
Takeki Uehara
Background: S-337395 is a novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV. This phase 2a, randomized, double-blind, placebo-controlled, single-center, proof-of-concept trial conducted in the United Kingdom (April-October 2024) evaluated the efficacy, safety, and dose-response relationship of S-337395 against RSV infection in a human challenge model. Methods: Healthy adults aged 18–55 years meeting predefined eligibility criteria were inoculated with RSV-A Memphis 37b on Day 0. Nasal washes were collected for quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assessment twice daily on Days 2–12 and once on Day 13. Participants were randomized 5:13:13:13:13 to receive S-337395 (1, 10, 30, or 300 mg) or placebo, once daily for 5 days upon evidence of infection. Efficacy analyses were conducted in participants with confirmed RSV infection in intent-to-treat infected (ITT-I) set. Safety was assessed in all randomized participants. Dose-response was evaluated across a wide dose range (1–300 mg). Results: Of 114 randomized participants, 60 comprised the ITT-I set. Covariate-adjusted mean viral load area under the curve (VL-AUC) was significantly lower in the 30- and 300-mg groups by qRT-PCR (64.87% and 88.94% reductions, respectively, both P < .05) and by viral culture assay (72.32% and 86.17% reductions, respectively, both P < .05). Total symptom score AUC was 78.15% lower in the 300-mg group (P < .05). S-337395 was well-tolerated without any safety concerns. Conclusions: S-337395 significantly reduced viral load, viral titer, and symptoms, and was well-tolerated in this human challenge study. Clinical Trial Registration: ISRCTN24865912.